Stem cell showdown: which transplant best keeps T-Cell cancer at bay?
NCT ID NCT07577531
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at two stem cell transplant methods—using a patient's own cells or a donor's cells—as a follow-up treatment for people with T-cell acute lymphoblastic leukemia or lymphoma who are in their first complete remission. The goal is to see which approach better prevents the cancer from coming back and improves survival. About 84 participants aged 14-55 will be observed over time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T CELL ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New combo therapy aims to beat tough blood cancer
- New maintenance therapy shows promise in preventing T-Cell cancer relapse after transplant
- Engineered immune cells take on tough childhood cancers
- Engineered immune cells take on tough T-Cell cancers in new trial
- Engineered immune cells take aim at stubborn leukemia after transplant
- Engineered immune cells take on tough blood cancers in early trial